| Back to main Menu |
| Back to Clinical |
The Heart Protection Study demonstrated that all cause mortality, vascular and stroke risk was significantly reduced by treating people at high risk of vascular disease with a statin (Heart Protection Study Collaborative Group, Lancet 2002; 360;7-22). Subsequent sub-group analyses demonstrated that in patients with prior stroke or TIA, statin therapy reduced risk of subsequent vascular events (Heart Protection Study Collaborative Group, Lancet 2004; 363:757-767). An economic analysis of this trial concluded that it was highly cost-effective to treat such patients (Heart Protection Study Collaborative Group, Lancet 2005; 365:1779-85).
Practices should report the percentage of patients on the stroke/TIA register who have a record of total cholesterol in the previous 15 months.
In verifying that this information has been correctly recorded, an inspection of the output from a computer search that has been used to provide information on this indicator could be used.
Prepared By Jean Keenan